Furthermore, Markosyan et al. observed a decrease in tumor cell proliferation and in vivo tumor burden with EphA2 KO, but we observed no differences in growth in vitro or in vivo when we knocked out EphA2 in our KPL model via CRISPR/Cas9 (Figure S4). The gene discussed is EPHA2; the disease is neoplasm.